Liraglutide vs Semaglutide

Summary: Semaglutide beats liraglutide on weight loss (15.8% vs 6.4% in STEP 8) and A1C (1.7% vs 1.0% in SUSTAIN 10), and dosing is once weekly instead of daily, but liraglutide still wins on coverage, pediatric Saxenda use, and cost for some patients.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

The short answer: semaglutide is the stronger drug. In head-to-head trials it produces about twice the weight loss of liraglutide and a bigger drop in A1C, and you inject it once a week instead of every day. Liraglutide is older, weaker on average, and dosed daily. It still gets prescribed, and there are real reasons why, but if someone hands you both options and asks which one works better, the honest answer is semaglutide.

Both drugs are made by Novo Nordisk. Both are GLP-1 receptor agonists. The choice between them comes down to a handful of practical questions: how much weight loss do you need, what does your insurance cover, can you tolerate daily injections, and is the patient an adolescent. The rest of this article walks through each of those.

The fast comparison

Generations of the same drug class

Liraglutide came first. The FDA approved Victoza in 2010 for type 2 diabetes, then Saxenda in 2014 for chronic weight management. It was the GLP-1 that proved this whole drug class could work for obesity, not just diabetes. The molecule has a fatty acid chain that binds it to albumin, which extends the half-life enough to make daily injections viable.

Semaglutide is the redesign. Novo Nordisk modified the GLP-1 backbone to resist enzymatic breakdown and to bind albumin more tightly. The result has a half-life around seven days, which is why Ozempic (approved 2017) and Wegovy (approved 2021) became weekly injections instead of daily. Same drug family, same receptor, same mechanism, longer-lasting molecule.

The redesign also turned out to be more potent on a per-week basis, not just more convenient. That is the part that drives the prescribing pattern today.

Efficacy: the head-to-head data

SUSTAIN 10: blood sugar

SUSTAIN 10 is the head-to-head trial that put semaglutide directly against liraglutide in adults with type 2 diabetes. It ran 30 weeks, enrolled 577 patients on background oral diabetes medications, and randomized them to weekly semaglutide 1.0 mg or daily liraglutide 1.2 mg ^[1].

Semaglutide reduced HbA1c by 1.7%. Liraglutide reduced it by 1.0%. That 0.7 percentage point gap is large in diabetes terms. For context, most A1C-lowering drugs are evaluated for whether they can deliver a 0.5% drop versus placebo. Beating an active comparator by 0.7% is meaningful.

Mean weight loss in SUSTAIN 10 was 5.8 kg (12.8 lb) on semaglutide versus 1.9 kg (4.2 lb) on liraglutide. Roughly three times the weight loss, in patients who were not selected for obesity, on a sub-maximum dose of semaglutide.

STEP 8: weight loss

STEP 8 was the obesity head-to-head. 338 adults with obesity (or overweight plus a comorbidity), no type 2 diabetes, randomized to weekly semaglutide 2.4 mg or daily liraglutide 3.0 mg, both with diet and exercise, for 68 weeks ^[2].

Mean weight loss was 15.8% on semaglutide and 6.4% on liraglutide. More than half of the semaglutide group lost at least 15% of their body weight. Only about 12% of the liraglutide group hit that threshold. This is the trial that built the "semaglutide is roughly 2.5x stronger" line you see quoted everywhere, and the math holds up.

Oral semaglutide vs injected liraglutide

In a 26-week diabetes trial, oral semaglutide (Rybelsus) at 14 mg daily was found noninferior to injected liraglutide 1.8 mg daily for A1C reduction ^[5]. So even the pill form of semaglutide is roughly equivalent to a near-maximum dose of injected liraglutide. The injectable semaglutide is then better than both.

Dosing and titration

Liraglutide (Saxenda) for weight loss

Daily subcutaneous injection. Titration takes five weeks ^[3]:

• Week 1: 0.6 mg/day
• Week 2: 1.2 mg/day
• Week 3: 1.8 mg/day
• Week 4: 2.4 mg/day
• Week 5 onward: 3.0 mg/day (maintenance)

Each step up is meant to reduce GI side effects. Some people stall at 2.4 mg if 3.0 mg causes too much nausea.

Semaglutide (Wegovy) for weight loss

Weekly subcutaneous injection. Titration takes 16 weeks ^[4]:

• Weeks 1 to 4: 0.25 mg weekly
• Weeks 5 to 8: 0.5 mg weekly
• Weeks 9 to 12: 1.0 mg weekly
• Weeks 13 to 16: 1.7 mg weekly
• Week 17 onward: 2.4 mg weekly (maintenance)

The Wegovy HD formulation adds a 7.2 mg weekly dose for adults who tolerated 2.4 mg for at least four weeks and want more weight loss.

The practical difference for patients is profound. Liraglutide users inject 365 times a year. Semaglutide users inject 52 times a year. That gap shows up in adherence data, in patient preference surveys, and in the prescribing habits of obesity specialists.

Side effects: same family, similar profile

Both drugs share the GLP-1 side effect signature: nausea, vomiting, diarrhea, constipation, abdominal pain. Mechanism dictates the symptom list, so the categories overlap almost completely.

The intensity differs, and the literature is split on which one is worse.

In SUSTAIN 10, more patients reported GI side effects on semaglutide (43.9%) than on liraglutide (11.4%), and more semaglutide patients discontinued treatment due to adverse events (38.3% vs 6.6%) ^[1]. That trial used semaglutide at 1.0 mg weekly against liraglutide at 1.2 mg daily. The semaglutide dose was effectively higher in pharmacologic terms, which explains some of the GI difference.

In STEP 8, both drugs caused similar rates of GI side effects at their respective maximum doses. About 84% of semaglutide patients and 83% of liraglutide patients had at least one GI event ^[2]. Severe events were rare in both arms.

The pattern that holds across both trials: semaglutide produces a steeper dose-response curve. Patients who titrate fast see more nausea, vomiting, and dropout. Patients who titrate slowly tolerate it about as well as liraglutide.

Both drugs carry the same boxed warning for medullary thyroid carcinoma and Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both warn about pancreatitis, gallbladder disease, acute kidney injury, hypoglycemia when combined with insulin or sulfonylureas, and aspiration risk during anesthesia.

Cost: the moving target

Without insurance, both drugs are expensive. The 2026 cash prices look like this.

Liraglutide retail without coupons:

• Saxenda (3 mg/day): around $1,349 to $1,600 per month
• Victoza (1.2 to 1.8 mg/day): around $543 to $815 per month
• Generic liraglutide for Victoza (FDA approved 2024): cheaper, but supply is still building

Semaglutide retail and NovoCare cash prices:

• Wegovy through NovoCare: $199/month for the first two fills at 0.25 or 0.5 mg, then $349/month for all doses thereafter
• Ozempic through NovoCare: $199/month for the first two fills, then $349 to $499/month depending on dose
• Rybelsus: about $1,000 to $1,200 monthly retail, lower with manufacturer savings card

The NovoCare cash program flipped the cost story in 2025 and 2026. Before that, Wegovy ran patients $1,300+ a month and Saxenda was the cheaper out-of-pocket option. Now Wegovy at $349 a month is roughly a quarter the price of brand-name Saxenda. That is one of the biggest reasons prescribers have shifted toward semaglutide for cash-pay patients.

With insurance, coverage varies. Plans tend to cover Ozempic and Victoza more readily than Wegovy or Saxenda because diabetes is a covered indication and weight loss often is not. Some plans will cover Saxenda when they will not cover Wegovy, which keeps liraglutide on the table for specific patients.

Oral options: Rybelsus, not liraglutide

Semaglutide has an oral version. Liraglutide does not. This is the practical asymmetry that matters for needle-averse patients.

Rybelsus is semaglutide formulated with a permeation enhancer (SNAC, sodium N-(8-(2-hydroxybenzoyl) amino) caprylate) that lets a small fraction of the molecule survive the stomach and absorb across the gastric epithelium. The bioavailability is poor (single digits) but consistent enough to deliver therapeutic blood levels at 3 mg, 7 mg, and 14 mg daily doses. Rybelsus is FDA approved for type 2 diabetes. The oral Wegovy tablet was approved in 2025 for chronic weight management and cardiovascular risk reduction.

Liraglutide cannot be made into a useful pill because the molecule is destroyed in the stomach and absorption is poor without a permeation enhancer matched to its chemistry. Novo Nordisk has not pursued an oral liraglutide product.

If a patient cannot or will not inject, semaglutide has an oral option. Liraglutide does not. That alone settles a lot of prescribing decisions.

When liraglutide still makes sense

Semaglutide wins on raw efficacy, dosing convenience, and increasingly on cash price. Liraglutide still gets prescribed because of:

1. Pediatric weight loss. Saxenda has FDA approval for chronic weight management in adolescents 12 years and older with obesity and body weight over 132 lb (60 kg). Wegovy was added for ages 12+ in 2022, so this gap is narrower than it used to be, but some pediatric specialists still prefer Saxenda because the daily titration gives more granular control over GI side effects in younger patients.

2. Insurance step therapy. Some plans require failure on liraglutide before covering semaglutide. You start on Saxenda not because it is the better choice but because the formulary says so.

3. GI sensitivity. A patient who could not tolerate any titration step of semaglutide sometimes does fine on liraglutide because the daily dose is smaller and the body never sits at a week-long peak.

4. Need for flexible dosing breaks. Liraglutide's short half-life lets patients skip individual days for social or work events without disrupting steady-state. Semaglutide is in your system all week whether you want it to be or not.

5. Cardiovascular indication in T2D. Victoza was approved to reduce major adverse cardiovascular events in adults with type 2 diabetes and established heart disease, based on the LEADER trial. Ozempic has similar approvals, so this rarely decides between them now, but Victoza was the first GLP-1 with that label.

6. Cash price for compounded liraglutide. Some compounding pharmacies and telehealth platforms offer compounded liraglutide for less than $200 a month, undercutting Wegovy even at the NovoCare price. Compounding semaglutide remains legally complicated since the FDA removed semaglutide from the shortage list.

Switching from Saxenda to Wegovy

A common transition. Patients tolerate Saxenda but plateau, and their prescriber moves them to semaglutide for more weight loss.

The protocol is straightforward. You take your final liraglutide dose, wait 24 hours, then start Wegovy at 0.25 mg. The standard Wegovy 16-week titration begins from there. You do not pick up semaglutide at a high dose just because you were already on a max dose of liraglutide. The GI receptors do not transfer tolerance one-to-one between molecules.

Expect a few weeks of GI symptoms returning during titration even if you had cleared them on Saxenda. The systems are different enough that your gut starts over.

Weight typically plateaus or rises slightly during the 0.25 and 0.5 mg weeks before semaglutide reaches a therapeutic dose. This is normal and resolves once the maintenance dose is reached.

Liraglutide vs semaglutide vs tirzepatide

Tirzepatide is the relevant third drug in this conversation. It is not a GLP-1 alone; it activates both GIP and GLP-1 receptors, and in the SURMOUNT-1 trial it produced about 21% weight loss at the 15 mg dose. Across head-to-head and indirect comparisons, the rough hierarchy for weight loss is:

• Tirzepatide (Mounjaro, Zepbound): 15 to 22% mean weight loss
• Semaglutide (Wegovy): 15 to 17% mean weight loss
• Liraglutide (Saxenda): 5 to 8% mean weight loss

So liraglutide is the weakest of the three modern incretin-based weight-loss drugs. It still works. It just works less.

For type 2 diabetes A1C reduction the order is similar: tirzepatide first, semaglutide second, liraglutide third.

Practical decision framework

Choose semaglutide if any of these apply:

• You want the most weight loss the GLP-1 class can deliver
• Daily injections are a non-starter for adherence
• You prefer an oral option (Rybelsus or oral Wegovy)
• Your insurance covers Ozempic or Wegovy
• You are cash-paying and can use NovoCare at $349/month

Choose liraglutide if any of these apply:

• You are titrating an adolescent and your specialist prefers daily granular control
• Your insurance covers Saxenda but not Wegovy
• You have failed semaglutide for GI reasons and need a gentler GLP-1
• You want the option to skip individual days around travel or events
• You can access cheap compounded liraglutide and cannot afford Wegovy

Most adult patients without a specific reason on the liraglutide side end up on semaglutide. That has been the prescribing pattern since 2022 and the cost story in 2025 to 2026 has accelerated it.

Common questions

Is liraglutide vs semaglutide which medication is better?

For weight loss and A1C reduction, semaglutide is better at maximum doses. STEP 8 showed 15.8% weight loss on semaglutide vs 6.4% on liraglutide. SUSTAIN 10 showed 1.7% vs 1.0% A1C reduction. Liraglutide is sometimes preferred in adolescents, in patients with severe GI sensitivity, or when insurance forces it.

How does liraglutide vs semaglutide cost compare?

Without insurance, Saxenda runs $1,349 to $1,600 per month while Wegovy through NovoCare is $349 per month after the first two fills. That price flip is recent. With insurance, coverage varies; some plans cover one but not the other.

Liraglutide vs Ozempic, what is the difference?

Ozempic is the type 2 diabetes brand of semaglutide. So this question is the same as liraglutide vs semaglutide, framed around the diabetes indication. Ozempic is a weekly injection; liraglutide (as Victoza) is daily. Ozempic produces larger A1C and weight reductions in head-to-head studies.

Victoza vs Ozempic, which is better?

Ozempic produced 1.7% A1C reduction vs 1.0% with Victoza-equivalent liraglutide in SUSTAIN 10, and roughly three times the weight loss. Ozempic is also weekly instead of daily. Victoza is still used in pediatric type 2 diabetes (approved ages 10+) where Ozempic does not have a pediatric label.

Victoza vs Saxenda, what is the difference?

Same molecule, different doses, different indications. Victoza tops out at 1.8 mg/day and is approved for type 2 diabetes. Saxenda goes up to 3.0 mg/day and is approved for chronic weight management. Both are liraglutide. Both are Novo Nordisk.

Saxenda vs Ozempic, what is the difference?

Saxenda is daily liraglutide for weight loss. Ozempic is weekly semaglutide for type 2 diabetes (often used off-label for weight loss). Different molecules, different schedules, different labels. If you have diabetes and weight to lose, Ozempic addresses both. If you have weight to lose without diabetes, Wegovy is the on-label semaglutide; Saxenda is the on-label liraglutide.

Wegovy vs Saxenda for side effects, which is worse?

At maximum doses (Wegovy 2.4 mg weekly, Saxenda 3.0 mg daily), rates of GI side effects are similar, about 83 to 84% of patients in STEP 8 reporting at least one event. Semaglutide tends to produce more severe nausea during rapid titration. Liraglutide tends to spread the GI burden more evenly across the week.

What should you expect when switching from Saxenda to Wegovy?

Stop Saxenda, wait 24 hours, start Wegovy at 0.25 mg weekly and titrate over 16 weeks. Expect GI side effects to return during titration even if you cleared them on Saxenda. Weight may plateau for the first 4 to 8 weeks until you reach a therapeutic semaglutide dose.

Can you take liraglutide and semaglutide together?

No. Both are GLP-1 receptor agonists, both bind the same receptor, and the prescribing information for each warns against using two GLP-1s at the same time. Combining them increases GI side effects and pancreatitis risk without improving outcomes.

Is liraglutide just the older version of semaglutide?

Functionally, yes. Same drug class, same receptor, same mechanism. Semaglutide is the redesigned version with a longer half-life and tighter receptor binding, which allows weekly dosing and produces larger effects per week. Liraglutide was approved in 2010, semaglutide in 2017.

Why is Saxenda still on the market if Wegovy works better?

Saxenda still has an FDA pediatric label, some insurance plans cover it when they will not cover Wegovy, and a subset of patients tolerate daily liraglutide better than weekly semaglutide. Novo Nordisk keeps it in production because there is real demand for those use cases.

Bottom line

Liraglutide is the first-generation GLP-1 for diabetes and obesity. Semaglutide is the second-generation redesign. Across the metrics that matter to most patients, weight loss, A1C control, dosing frequency, and now even cash price, semaglutide is stronger. The reasons to still use liraglutide are specific: pediatric care, GI sensitivity, insurance step therapy, or a need for daily dosing flexibility. If none of those apply, semaglutide is the default. The data has been pointing that direction since 2017, and the prescribing pattern has finally caught up.